HuniLife Biotechnology, Inc.
Update：2025/12/03
Industries
Main Industry
Biotechnology
Main Product/Service
HuniLife is committed to developing first-in-class therapeutics for unmet medical need, indicating the innovation-pursuing nature of HuniLife. The products in development at HuniLife are acquired from renowned research institutes or companies through licensing or co-development. HuniLife plans to enable these products to be tested in clinic as soon as the required preclinical development works are completed.
Founded Year
2013
Unified Business No.
52278884
Status
Active
Number of Employees
9
Total Paid-in
Capital
117,515,640 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
HuniLife Biotechnology, Inc. is a Taiwan-based biopharmaceutical company founded in 2013. HuniLife strives to develop efficacious therapeutics for the treatment of human diseases while aiming to bring long lasting value to our shareholders. We are now developing new generation of novel drugs for unmet medical needs.
The ENO1-targeting therapeutic, HuL001, is a humanized monoclonal antibody for the treatment of immune diseases or cancers. HuL001 is a novel First-in-Class drug to treat immune diseases or cancers owing to its unique mechanism of action (MOA). ENO1-targeting antibody is derived from the collaboration efforts from Development Center for Biotechnology (DCB) and National Health Research Institute (NHRI) in Taiwan.
In addition, HuniLife has continuous efforts to substantiate its R&D pipeline, which includes HuL003 (antibody drug conjugates, ADC) for the treatment of various cancers. HuL003 is a ENO1-based ADC for oncology application.
The ENO1-targeting therapeutic, HuL001, is a humanized monoclonal antibody for the treatment of immune diseases or cancers. HuL001 is a novel First-in-Class drug to treat immune diseases or cancers owing to its unique mechanism of action (MOA). ENO1-targeting antibody is derived from the collaboration efforts from Development Center for Biotechnology (DCB) and National Health Research Institute (NHRI) in Taiwan.
In addition, HuniLife has continuous efforts to substantiate its R&D pipeline, which includes HuL003 (antibody drug conjugates, ADC) for the treatment of various cancers. HuL003 is a ENO1-based ADC for oncology application.
